酒精性肝病

参考文献

关键文献

Heimbach J, Kulik LM, Finn R, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-80.全文  摘要

Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997 Jan;25(1):108-11.全文  摘要

参考文献

1. Axley PD, Richardson CT, Singal AK. Epidemiology of alcohol consumption and societal burden of alcoholism and alcoholic liver disease. Clin Liver Dis. 2019 Feb;23(1):39-50. 摘要

2. World Health Organization. Fact sheet: alcohol. Sep 2018 [internet publication].全文

3. Julien J, Ayer T, Bethea ED, et al. Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study. Lancet Public Health. 2020 Jun;5(6):e316-e323.全文  摘要

4. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2018 national survey on drug use and health. 2019 [internet publication].全文

5. National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health. Alcohol facts and statistics. Jun 2021 [internet publication].全文

6. Centers for Disease Control and Prevention. Alcohol and public health: alcohol-related disease impact (ARDI). Sept 2020 [internet publication].全文

7. Grucza RA, Sher KJ, Kerr WC, et al. Trends in adult alcohol use and binge drinking in the early 21st-century United States: a meta-analysis of 6 national survey series. Alcohol Clin Exp Res. 2018 Oct;42(10):1939-50. 摘要

8. Dang K, Hirode G, Singal AK, et al. Alcoholic liver disease epidemiology in the United States: a retrospective analysis of 3 US databases. Am J Gastroenterol. 2020 Jan;115(1):96-104. 摘要

9. Public Health England. Official statistics: Liver disease profiles: short statistical commentary, October 2018. Oct 2018 [internet publication].全文

10. Rehm J, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 2010 Jul;29(4):437-45. 摘要

11. Singal AK, Bataller R, Ahn J, et al. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol. 2018 Feb;113(2):175-94.全文  摘要

12. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011 Nov;141(5):1572-85.全文  摘要

13. Mueller S, Millonig G, Seitz HK. Alcoholic liver disease and hepatitis C: a frequently underestimated combination. World J Gastroenterol. 2009 Jul 28;15(28):3462-71.全文  摘要

14. Raynard B, Balian A, Fallik D, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology. 2002 Mar;35(3):635-8.全文  摘要

15. Hart CL, Morrison DS, Batty GD, et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ. 2010 Mar 11;340:c1240.全文  摘要

16. Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol. 1992 Nov 15;136(10):1248-57. 摘要

17. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology. 2004 Nov;127(5 Suppl 1):S87-96. 摘要

18. Zhao YY, Xiao M, Zhang CL, et al. Associations between the tumor necrosis factor-α gene and interleukin-10 gene polymorphisms and risk of alcoholic liver disease: A meta-analysis. Clin Res Hepatol Gastroenterol. 2016 Sep;40(4):428-39. 摘要

19. Wang X, Yan Z, Ye Q. Interleukin-6 gene polymorphisms and susceptibility to liver diseases: A meta-analysis. Medicine (Baltimore). 2019 Dec;98(50):e18408.全文  摘要

20. Salameh H, Raff E, Erwin A, et al. PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. Am J Gastroenterol. 2015 Jun;110(6):846-56. 摘要

21. Li Y, Zhou J. Roles of silent information regulator 1-serine/arginine-rich splicing factor 10-lipin 1 axis in the pathogenesis of alcohol fatty liver disease. Exp Biol Med (Maywood). 2017 Jun;242(11):1117-25.全文  摘要

22. Mendenhall CL, Seeff L, Diehl AM, et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. Hepatology. 1991 Oct;14(4 Pt 1):581-9. 摘要

23. Caldwell SH, Li X, Rourk RM, et al. Hepatitis C infection by polymerase chain reaction in alcoholics: false-positive ELISA results and the influence of infection on a clinical prognostic score. Am J Gastroenterol. 1993 Jul;88(7):1016-21. 摘要

24. Loft S, Olesen KL, Dossing M. Increased susceptibility to liver disease in relation to alcohol consumption in women. Scand J Gastroenterol. 1987 Dec;22(10):1251-6. 摘要

25. National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health. Women and alcohol. Jun 2019 [internet publication].全文

26. Seitz HK, Stickel F. Alcoholic liver disease in the elderly. Clin Geriatr Med. 2007 Nov;23(4):905-21. 摘要

27. National Institute on Alcohol Abuse and Alcoholism. Surveillance report 111: Liver cirrhosis mortality in the United States: national, state, and regional trends, 2000–2015. April 2018 [internet publication].全文

28. Kochanek KD, Murphy SL, Xu J, et al. Deaths: final data for 2017. Natl Vital Stat Rep. 2019 Jun;68(9):1-77.全文  摘要

29. Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020 Jan;71(1):306-33.全文  摘要

30. Buchsbaum DG, Buchanan RG, Centor RM, et al. Screening for alcohol abuse using CAGE scores and likelihood ratios. Ann Intern Med. 1991 Nov 15;115(10):774-7. 摘要

31. Girela E, Villanueva E, Hernandez-Cueto C, et al. Comparison of the CAGE questionnaire versus some biochemical markers in the diagnosis of alcoholism. Alcohol Alcohol. 1994 May;29(3):337-43. 摘要

32. Aalto M, Alho H, Halme JT, et al. AUDIT and its abbreviated versions in detecting heavy and binge drinking in a general population survey. Drug Alcohol Depend. 2009 Jul 1;103(1-2):25-9. 摘要

33. European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol. 2018 Jul;69(1):154-81.全文  摘要

34. Senousy BE, Draganov PV. Evaluation and management of patients with refractory ascites. World J Gastroenterol. 2009 Jan 7;15(1):67-80.全文  摘要

35. Ahmed Z, Ahmed U, Walayat S, et al. Liver function tests in identifying patients with liver disease. Clin Exp Gastroenterol. 2018;11:301-7.全文  摘要

36. Cohen JA, Kaplan MM. The SGOT/SGPT ratio - an indicator of alcoholic liver disease. Dig Dis Sci. 1979 Nov;24(11):835-8. 摘要

37. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017 Jan;112(1):18-35.全文  摘要

38. Koperdanova M, Cullis JO. Interpreting raised serum ferritin levels. BMJ. 2015 Aug 3;351:h3692.全文  摘要

39. Yersin B, Nicolet JF, Dercrey H, et al. Screening for excessive alcohol drinking: comparative value of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume. Arch Intern Med. 1995 Sep 25;155(17):1907-11. 摘要

40. Stauber RE, Stepan V, Trauner M, et al. Evaluation of carbohydrate-deficient transferrin for detection of alcohol abuse in patients with liver dysfunction. Alcohol Alcohol. 1995 Mar;30(2):171-6. 摘要

41. Lumeng L. New diagnostic markers of alcohol abuse. Hepatology. 1986 Jul-Aug;6(4):742-5. 摘要

42. Moreno C, Mueller S, Szabo G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J Hepatol. 2019 Feb;70(2):273-83.全文  摘要

43. Pavlov CS, Casazza G, Nikolova D, et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev. 2015 Jan 22;1:CD010542.全文  摘要

44. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med. 1989 Sep 15;111(6):473-8. 摘要

45. Mathurin P, Duchatelle V, Ramond MJ, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology. 1996 Jun;110(6):1847-53. 摘要

46. Shawcross DL, Dunk AA, Jalan R, et al. How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. Eur J Gastroenterol Hepatol. 2016 Feb;28(2):146-52.全文  摘要

47. Bell H, Tallaksen CM, Try K, et al. Carbohydrate-deficient transferrin and other markers of high alcohol consumption: a study of 502 patients admitted consecutively to a medical department. Alcohol Clin Exp Res. 1994 Oct;18(5):1103-8. 摘要

48. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002 Jul 2;137(1):1-10. 摘要

49. Marsano LS, Mendez C, Hill D, et al. Diagnosis and treatment of alcoholic liver disease and its complications. Alcohol Res Health. 2003;27(3):247-56.全文  摘要

50. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009 Jul;30(1):37-47. 摘要

51. US Preventive Services Task Force., Curry SJ, Krist AH, et al. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2018 Nov 13;320(18):1899-1909.全文  摘要

52. Hoeksema HL, de Bock GH. The value of laboratory tests for the screening and recognition of alcohol abuse in primary care patients. J Fam Pract. 1993 Sep;37(3):268-76. 摘要

53. Thompson Coon J, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess. 2007 Sep;11(34):1-206.全文  摘要

54. Heimbach J, Kulik LM, Finn R, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-80.全文  摘要

55. Berry PA, Thomson SJ, Rahman TM, et al. Review article: towards a considered and ethical approach to organ support in critically-ill patients with cirrhosis. Aliment Pharmacol Ther. 2013 Jan;37(2):174-82.全文  摘要

56. Powell WJ Jr, Klatskin G. Duration of survival in patients with Laennec's cirrhosis: influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med. 1968 Mar;44(3):406-20. 摘要

57. Veldt BJ, Laine F, Guillygomarc'h A, et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol. 2002 Jan;36(1):93-8. 摘要

58. Altamirano J, López-Pelayo H, Michelena J, et al. Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: prediction and impact on long-term survival. Hepatology. 2017 Dec;66(6):1842-53.全文  摘要

59. Naveau S, Giraud V, Borotto E, et al. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997 Jan;25(1):108-11.全文  摘要

60. Umemura T, Ichijo T, Matsumoto A, et al. Severe hepatic injury caused by orlistat. Am J Med. 2006 Aug;119(8):e7. 摘要

61. Sall D, Wang J, Rashkin M, et al. Orlistat-induced fulminant hepatic failure. Clin Obes. 2014 Dec;4(6):342-7. 摘要

62. Wakim-Fleming J, Mullen KD. Long-term management of alcoholic liver disease. Clin Liver Dis. 2005 Feb;9(1):135-49. 摘要

63. McCullough AJ, Tavill AS. Disordered energy and protein metabolism in liver disease. Semin Liver Dis. 1991 Nov;11(4):265-77. 摘要

64. McCullough AJ, Bugianesi E. Protein-calorie malnutrition and the etiology of cirrhosis. Am J Gastroenterol. 1997 May;92(5):734-8. 摘要

65. Vasco M, Paolillo R, Schiano C, et al. Compromised nutritional status in patients with end-stage liver disease: role of gut microbiota. Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):290-300.全文  摘要

66. Swart GR, Zillikens MC, van Vuure JK, et al. Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver. BMJ. 1989 Nov 11;299(6709):1202-3.全文  摘要

67. Verboeket-Van De Venne WP, Westerterp KR, Van Hoek B, et al. Habitual pattern of food intake in patients with liver disease. Clin Nutr. 1993 Oct;12(5):293-7. 摘要

68. Stickel F, Hoehn B, Schuppan D, et al. Review article: nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther. 2003 Aug 15;18(4):357-73.全文  摘要

69. Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2005 Jul;3(7):705-13.全文  摘要

70. Moreno C, Langlet P, Hittelet A, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. J Hepatol. 2010 Dec;53(6):1117-22. 摘要

71. Antar R, Wong P, Ghali P. A meta-analysis of nutritional supplementation for management of hospitalized alcoholic hepatitis. Can J Gastroenterol. 2012 Jul;26(7):463-7. 摘要

72. Gluud LL, Dam G, Les I, et al. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017 May 18;(5):CD001939.全文  摘要

73. Koretz RL. The evidence for the use of nutritional support in liver disease. Curr Opin Gastroenterol. 2014 Mar;30(2):208-14. 摘要

74. Ney M, Vandermeer B, van Zanten SJ, et al. Meta-analysis: oral or enteral nutritional supplementation in cirrhosis. Aliment Pharmacol Ther. 2013 Apr;37(7):672-9.全文  摘要

75. McCullough AJ, O'Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol. 1998 Nov;93(11):2022-36.全文  摘要

76. Barve A, Khan R, Marsano L, et al. Treatment of alcoholic liver disease. Ann Hepatol. 2008 Jan-Mar;7(1):5-15. 摘要

77. Louvet A, Thursz MR, Kim DJ, et al. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo: a meta-analysis of individual data from controlled trials. Gastroenterology. 2018 Aug;155(2):458-68. 摘要

78. Pavlov CS, Varganova DL, Casazza G, et al. Glucocorticosteroids for people with alcoholic hepatitis. Cochrane Database Syst Rev. 2019 Apr 9;(4):CD001511.全文  摘要

79. Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial. Ann Intern Med. 1989 May 1;110(9):685-90. 摘要

80. Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011 Feb;60(2):255-60. 摘要

81. Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology. 2003 Dec;38(6):1363-9.全文  摘要

82. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007 Jun;45(6):1348-54.全文  摘要

83. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med. 1990 Aug 15;113(4):299-307. 摘要

84. Mathurin P. Is alcoholic hepatitis an indication for transplantation? Current management and outcomes. Liver Transpl. 2005 Nov;(11 suppl 2):S21-4.全文  摘要

85. Hmoud BS, Patel K, Bataller R, et al. Corticosteroids and occurrence of and mortality from infections in severe alcoholic hepatitis: a meta-analysis of randomized trials. Liver Int. 2016 May;36(5):721-8. 摘要

86. Tilg H, Jalan R, Kaser A, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol. 2003 Apr;38(4):419-25. 摘要

87. Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004 May;39(5):1390-7.全文  摘要

88. Runyon BA, AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013 Apr;57(4):1651-3.全文  摘要

89. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010 Sep;53(3):397-417.全文  摘要

90. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006 Oct;55 Suppl 6:vi1-12.全文  摘要

91. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397-417.全文  摘要

92. Kuiper JJ, van Buuren HR, de Man RA. Ascites in cirrhosis: a review of management and complications. Neth J Med. 2007;65(8):283-8.全文  摘要

93. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000;32(1):142-53. 摘要

94. Bernardi M, Carceni P, Navickis RJ, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012 Apr;55(4):1172-81.全文  摘要

95. Loomba R, Wesley R, Bain A, et al. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol. 2009 Apr;7(4):487-93. 摘要

96. Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology. 1994 Nov;20(5):1115-20. 摘要

97. Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol. 1996 Jul;91(7):1374-9. 摘要

98. Keeffe EB. Comorbidities of alcoholic liver disease that affect outcome of orthotopic liver transplantation. Liver Transpl Surg. 1997 May;3(3):251-7. 摘要

99. Gong A, Minuk GY. Predictors of alcohol relapse following liver transplantation for alcohol-induced liver failure. consideration of "A-D" selection criteria. Ann Transplant. 2018 Feb 20;23:129-35.全文  摘要

100. Obed A, Bashir A, Stern S, et al. Severe acute alcoholic hepatitis and liver transplant: a never-ending mournful story. Clin Mol Hepatol. 2018 Dec;24(4):358-66.全文  摘要

101. Dunn W, Jamil LH, Brown LS, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005 Feb;41(2):353-8.全文  摘要

102. Marot A, Dubois M, Trépo E, et al. Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis. PLoS One. 2018 Jan 11;13(1):e0190823.全文  摘要

103. Al-Saeedi M, Barout MH, Probst P, et al. Meta-analysis of patient survival and rate of alcohol relapse in liver-transplanted patients for acute alcoholic hepatitis. Langenbecks Arch Surg. 2018 Nov;403(7):825-36.全文  摘要

104. Singh V, Keisham A, Bhalla A, et al. Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis. Clin Gastroenterol Hepatol. 2018 Oct;16(10):1650-6.全文  摘要

105. Thompson J, Jones N, Al-Khafaji A, et al. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial. Liver Transpl. 2018 Mar;24(3):380-93.全文  摘要

106. Philips CA, Pande A, Shasthry SM, et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study. Clin Gastroenterol Hepatol. 2017 Apr;15(4):600-2. 摘要

107. Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011 Nov 10;365(19):1781-9.全文  摘要

108. Singh S, Murad MH, Chandar AK, et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis. Gastroenterology. 2015 Oct;149(4):958-70.e12.全文  摘要

109. Saunders JB, Latt N. Epidemiology of alcoholic liver disease. Baillieres Clin Gastroenterol. 1993 Sep;7(3):555-79. 摘要

110. Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978 Aug;75(2):193-9. 摘要

111. Ramond MJ, Poynard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med. 1992 Feb 20;326(8):507-12.全文  摘要

112. Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005 Aug;54(8):1174-9.全文  摘要

113. Bajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009 Oct;50(4):1175-83. 摘要

114. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010 Sep 8;(9):CD002907.全文  摘要

115. Garcia-Tsao G, Sanyal AJ, Grace ND, et al; Practice Guidelines Committee of American Association for Study of Liver Diseases; Practice Parameters Committee of American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol. 2007 Sep;102(9):2086-102. 摘要

116. Yang J, Guo Z, Wu Z, et al. Antacids for preventing oesophagogastric variceal bleeding and rebleeding in cirrhotic patients. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005443.全文  摘要

117. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013 Jan 3;368(1):11-21.全文  摘要

118. Karwa R, Woodis CB. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. Ann Pharmacother. 2009 Apr;43(4):692-9. 摘要

119. Sagi SV, Mittal S, Kasturi KS, et al. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: A meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2010 May;25(5):880-5. 摘要

120. Kim DK, Riley LE, Harriman KH, et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Feb 10;66(5):136-8.全文  摘要

121. Speeg KV, Bay MK. Prevention and treatment of drug-induced liver disease. Gastroenterol Clin North Am. 1995 Dec;24(4):1047-64. 摘要

内容使用需遵循免责声明